Citius Pharmaceuticals (CTXR) Total Non-Current Liabilities (2014 - 2017)

Citius Pharmaceuticals (CTXR) has reported Total Non-Current Liabilities for 4 consecutive years, with $9.4 million the latest figure, recorded in Q2 2017.

• For the quarter ending Q2 2017, Total Non-Current Liabilities rose 392.73% year-over-year to $9.4 million; the trailing twelve-month figure through Jun 2017 stood at $9.4 million (up 392.73% YoY), and the FY2016 full-year result was $3.5 million, up 449.08% from the prior year.
• Total Non-Current Liabilities climbed to $9.4 million in Q2 2017 per CTXR's latest filing, from $6.9 million in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $9.4 million in Q2 2017 and bottomed at $255730.0 in Q4 2014.
• Historically, Total Non-Current Liabilities has averaged $2.8 million across 4 years, with a median of $1.5 million in 2015.
• The sharpest annual moves came in 2015 and 2016: Total Non-Current Liabilities decreased 24.83% in 2015, then soared 550.07% in 2016.
• Over 4 years, Total Non-Current Liabilities stood at $255730.0 in 2014, then surged by 316.09% to $1.1 million in 2015, then jumped by 408.25% to $5.4 million in 2016, then jumped by 73.67% to $9.4 million in 2017.
• According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $9.4 million, $6.9 million, and $5.4 million for Q2 2017, Q1 2017, and Q4 2016 respectively.